These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22474114)

  • 1. Survival analysis.
    Kim J
    Pediatr Rev; 2012 Apr; 33(4):172-4. PubMed ID: 22474114
    [No Abstract]   [Full Text] [Related]  

  • 2. The U.S. trials in adult acute lymphoblastic leukemia.
    Larson RA
    Ann Hematol; 2004; 83 Suppl 1():S127-8. PubMed ID: 15124704
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
    Leoni V; Biondi A
    Haematologica; 2015 Mar; 100(3):295-9. PubMed ID: 25740105
    [No Abstract]   [Full Text] [Related]  

  • 5. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.
    Yamaji K; Okamoto T; Yokota S; Watanabe A; Horikoshi Y; Asami K; Kikuta A; Hyakuna N; Saikawa Y; Ueyama J; Watanabe T; Okada M; Taga T; Kanegane H; Kogawa K; Chin M; Iwai A; Matsushita T; Shimomura Y; Hori T; Tsurusawa M;
    Pediatr Blood Cancer; 2010 Dec; 55(7):1287-95. PubMed ID: 20535816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):5-9. PubMed ID: 19149913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients.
    Gao C; Zhao XX; Li WJ; Cui L; Zhao W; Liu SG; Yue ZX; Jiao Y; Wu MY; Li ZG
    Am J Hematol; 2012 Nov; 87(11):1022-7. PubMed ID: 22911440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
    Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
    J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
    von Stackelberg A; Seeger K; Henze G; Eckert C
    Leukemia; 2004 Oct; 18(10):1727-8; author reply 1728-9. PubMed ID: 15356653
    [No Abstract]   [Full Text] [Related]  

  • 11. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
    Horstmann MA; Hassenpflug WA; zur Stadt U; Escherich G; Janka G; Kabisch H
    Haematologica; 2005 Dec; 90(12):1701-3. PubMed ID: 16330449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of minimal residual disease testing during the second year of disease: still no answer?
    Aricò M; Conter V; Valsecchi MG; Masera G
    J Clin Oncol; 2003 Dec; 21(23):4463-4; author reply 4464-5. PubMed ID: 14645441
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia.
    Eckert C; Biondi A; Seeger K; Cazzaniga G; Hartmann R; Beyermann B; Pogodda M; Proba J; Henze G
    Lancet; 2001 Oct; 358(9289):1239-41. PubMed ID: 11675066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in allogeneic and autologous BMT for acute lymphoblastic leukaemia (ALL).
    Barrett J
    Bone Marrow Transplant; 1991; 7 Suppl 2():59-61. PubMed ID: 1878722
    [No Abstract]   [Full Text] [Related]  

  • 16. Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia.
    Advani AS
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):776-7. PubMed ID: 22252580
    [No Abstract]   [Full Text] [Related]  

  • 17. Nutritional status of children during treatment for acute lymphoblastic leukemia in Guatemala.
    Antillon F; Rossi E; Molina AL; Sala A; Pencharz P; Valsecchi MG; Barr R
    Pediatr Blood Cancer; 2013 Jun; 60(6):911-5. PubMed ID: 23109269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 expression and poor prognosis in childhood acute lymphoblastic leukemia.
    Hecker S; Sauerbrey A; Volm M
    Anticancer Res; 1994; 14(6B):2759-61. PubMed ID: 7872714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia.
    Brozek J; Bryl E; Płoszyńska A; Balcerska A; Witkowski JM
    J Pediatr Hematol Oncol; 2009 Jul; 31(7):493-9. PubMed ID: 19564743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blinatumomab in acute lymphoblastic leukemia.
    Thomas X; Lejeune C
    Expert Rev Anticancer Ther; 2016; 16(3):251-3. PubMed ID: 26775917
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.